Comparison of intravenous ferric carboxymaltose and iron sucrose complex for the treatment of iron deficiency anaemia in pregnancy

Comparison of efficacy and safety of intravenous ferric carboxymaltose and iron sucrose complex for the treatment of iron deficiency anaemia in pregnancy: A randomised controlled study - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/063025

Enrollment

100

Registered

2024-02-22

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O99- Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium

Interventions

Intervention1: Iron sucrose, ferric carboxymaltose: Iron preparation given as intravenous infusion to correct anaemia, given as an infusion with normal saline over 30 minutes and helpful in correctin

Eligibility

Inclusion criteria

Inclusion criteria: 1-Pregnant women from 20 weeks to 36 weeks period of gestation 2-Haemoglobin more than 7 g% and less than 11g% 3-Having pure iron deficiency anaemia: baseline serum ferritin

Exclusion criteria

Exclusion criteria: 1-History of allergy to IV iron preparation 2-Chronic infections like HIV/ TB/hepatitis 3-Known case of chronic heart/ lung disease

Design outcomes

Primary

Measure	Time frame
Rise in haemoglobin and hematocrit from baseline in 4 weeks expressed as Mean ± Standard Deviation and percentage rise from baseline.Timepoint: Rise in haemoglobin and hematocrit from baseline in 4 weeks expressed as Mean ± Standard Deviation and percentage rise from baseline.	—

Secondary

Measure	Time frame
1. Rise in ferritin levels as Mean ± Standard Deviation in both groups. 2. The rate of adverse effects in both groups (local site reaction, allergic reaction and anaphylaxis) 3. Change in FACIT Fatigue score baseline and at 4 weeks in two groups.Timepoint: 0 and 4 weeks	—

Countries

India

Contacts

Public ContactDr Krishna Agarwal

Lok nayak hospital

drkrishna.agarwal@gmail.com9968604350

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026